Summaries by Inventor DiPersio, John

HoxB5 cDTR mice
DiPersio, John ; Karpova, Darja
T-018897

— Transgenic HoxB5 conditional DTR (cDTR) mice have been generated using CRISPR mediated targeting of the HoxB5 gene (exon2) in fertilized wildtype C57Bl/6 eggs that were then microinjected into pseudopregnant wildtype female mice. The construct targeted under the controls of the endogenous HoxB5 prom…

Interferon-gamma treatment to improve efficacy of hematopoietic stem cell transplantation for AML and other cancer
Christopher, Matthew ; DiPersio, John ; Ley, Timothy ; Petti, Allegra ; Rettig, Michael
T-018954

— Technology Description Researchers at Washington University in St. Louis have discovered that interferon-gamma treatment could potentially prevent relapse after hematopoietic stem cell transplantation (HCT) treatment by making the cancer cells more visible to the donor immune cells. This technolog…

JAK inhibitor as conditioning agent for allogeneic hematopoietic stem cell transplantation
DiPersio, John ; Persaud, Stephen "Steve"
T-019132

— Technology Description Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…

Predictive biomarker for CAR T-associated neurotoxicity
Ances, Beau ; Butt, Omar ; DiPersio, John ; Ghobadi, Armin
T-019528

— Technology Description: Researchers at Washington University in St. Louis have developed a biomarker screening assay to predict which patients receiving CAR T cell therapy will experience neurotoxicity. Patients can be screened well in advance of receiving the T cell therapy with a simple serum as…

PI3K inhibitors to treat Cytokine Release Syndrome
Amatya, Parmeshwar ; Carter, Alun ; Cooper, Matthew ; DiPersio, John
T-019429

— Technology Description A team of researchers, led by John DiPersio and Matthew Cooper at Washington University in St. Louis, have identified a small molecule kinase inhibitor capable of mitigating cytokine release syndrome following CAR-T cell therapy. PI3K inhibitors can suppress production of IL-…